Mobile

A Phase 3 Randomized, Double-Blind, Placebo- and Oxycodone-Controlled, Multicenter Study of the Efficacy and Safety of Tanezumab in Patients with Osteoarthritis of the Knee or Hip

Update Il y a 4 ans
Reference: EUCTR2009-013329-41

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

• Demonstrate superior analgesic efficacy of tanezumab 10 mg and 5 mg administered IV every 8 weeks compared to placebo at Week 16. • Demonstrate non-inferiority and, if warranted, superior analgesic efficacy of tanezumab 10 mg and 5 mg administered IV every 8 weeks compared to oxycodone HCl controlled release (CR) tablets (Oxycontin) 10-40 mg every 12 hours (q12h) at Week 16.

Inclusion criteria

  • osteoarthritis of the knee and hip

Links